NOTE
21 – RELATED PARTIES TRANSACTIONS
| a. | Related
Parties presented in the consolidated statements of comprehensive loss |
SCHEDULE
OF RELATED PARTY TRANSACTIONS
| | |
| Years
ended December 31, | |
| | |
| 2024 | | |
| 2023 | |
| | |
| (in
thousands) | |
| Stock-based
compensation expenses to executive officers | |
$ | 89 | | |
$ | 78 | |
| Stock-based compensation
expenses to Board Members | |
$ | 405 | | |
$ | 99 | |
| Compensation of executive
officers | |
$ | 323 | | |
$ | 690 | |
| Management and consulting
fees to Board Members | |
$ | 277 | | |
$ | 380 | |
| b. |
Related Parties presented in the consolidated balance
sheets |
SCHEDULE
OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS
| | |
December 31, | |
| | |
2024 | | |
2023 | |
| | |
(in thousands) | |
| Executive officers’ payables | |
$ | 225 | | |
$ | 150 | |
| Non-executive directors’ payable | |
$ | 543 | | |
$ | 938 | |
| Amounts payable Orgenesis Biotech Israel Ltd | |
$ | (2,695 | ) | |
$ | - | |
|